Fuzzy math? No. Here is another consideration. Abbott's current PSA screening test for prostate cancer is based on the Prostate Specific Antigen (PSA) marker which has a 67% sensitivity. BOCX indicates that the current PSA market is approximately 450 million a year. In other words, about a half "blockbuster" product. BOCX also states that tests show their RECAF technology has a 95% sensitivity for prostate cancer. If that is factually correct, it would be logical that the RECAF technology would be used in a new PSA screening test that I have suggested Abbott might call "PSA II" just for the name recognition in marketing to doctors. But with this new test, (I am assuming that Abbott would abandon its old technology with the 67% sensitivity) it would appear that BOCX could possibly be in line to receive 10% royalties, or about 45 million a year, with no expense to BOCX to earn that revenue except for maintaining a bank account to receive the royalties. Also, there is little doubt that a prostate, cancer-screening test with 95% sensitivity would also grow the market for the test. This is precisely the blood serum technology that Abbott licensed almost a year ago, and we are not talking about something that would arrive on the market years from now. This is all about Abbott staying on the forefront of the cancer diagnostics market, and maintaining the double-digit annual sales growth that Abbott likes to talk about at their conference calls. kag
